52-Week Trial Results Of Adalimumab As Novel Therapy For Refractory, Progressive Pulmonary Sarcoidosis
Nadera Sweiss(University of Illinois Chicago), Michael H. Ellman(University of Chicago), Robert P. Baughman(University of Cincinnati), Aileen L. Pangan(AbbVie (United States)), Philip Caligiuri, Edward T. Naureckas(University of Chicago), James F. Curran(University of Chicago), Timothy B. Niewold(Hospital for Special Surgery), D. Kyle Hogarth(MACOM (United States)), Marisa Alegre(Erasmus Hospital), Mary E. Strek(University of Chicago), Imre Noth(University of Virginia)
Cited by 2
Related Papers
Serum Cytokine Levels in Human Septic Shock
|CHEST Journal|1993|888
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis
|Critical Care Medicine|1997|863
ERS clinical practice guidelines on treatment of sarcoidosis
|European Respiratory Journal|2021|579